Arcutis Biotherapeutics, Inc. Common Stock
ARQTArcutis Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing dermatology and inflammatory disease treatments. Founded to innovate within the skin disease space, it emphasizes targeted therapies for conditions such as psoriasis, atopic dermatitis, and other inflammatory skin disorders.
Company News
Arcutis Biotherapeutics announced it will report Q4 and full year 2025 financial results on February 25, 2026, followed by a conference call at 4:30 p.m. ET. The company will also present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. Arcutis highlighted 2026 strategic priorities and announced a nationwide survey address...
A nationwide survey of 1,500 respondents reveals that nearly 9 in 10 adults and parents with chronic inflammatory skin conditions are concerned about topical steroid side effects, and approximately 8 in 10 report their treatment plans focus on reactive flare management rather than proactive long-term disease management. The survey highlights sign...
Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk ...
Arcutis Biotherapeutics is a promising biotech company with its key drug Zoryve, treating inflammatory skin diseases. The company shows strong sales growth, potential peak sales of $2.6-$3.5 billion, and is expanding its drug approvals across multiple indications.
Arcutis Biotherapeutics appointed Amit Munshi to its Board of Directors and announced the retirement of founder Bhaskar Chaudhuri, marking a leadership transition for the biopharmaceutical company.
